Pharmacor Analyst Calls

Pharmacor analyst calls are available exclusively to clients who subscribe to the Pharmacor advisory service being featured in the online presentation. Recordings of the presentations are also available for playback following each session. Topics covered in Pharmacor analyst calls include detailed and timely analysis on:

• How a newly launched drug will compete in the market and how it will impact the market share of other currently marketed therapies
• What the impact of corporate announcements and presentations at biopharmaceutical conferences will have on the marketplace
• How a drug’s regulatory rejection will impact the market, including insight on what other existing therapies will inherit the failed agent’s market share
• How positive clinical trial data will impact thought leaders’ perceptions of a drug candidate and how that agent would be prescribed if approved
• How a market currently dominated by a certain drug class will evolve as emerging therapies from other drug classes steal share from dominant therapies over time
• Which agents in a crowded therapeutic pipeline are best positioned to have the greatest impact on treatment and, as a result, will be the most successful

• Dyslipidemia: How Will the Discontinuation of Roche/Japan Tobacco’s Dalcetrapib Impact the Future Prospects for Other HDL-C Modulating Agents? - Upcoming
  May 24, 2012
  Based on our Pharmacor Dyslipidemia advisory service, Decision Resources is offering this exclusive analyst call entitled Dyslipidemia: How Will the Discontinuation of Roche/Japan Tobacco’s Dalcetrapib Impact the Future Prospects for Other HDL-C Modulating Agents?
  
  This analyst call wil be held on May 24, 2012. 
  
  Click here to view the invite.
  
  
  Read More
• Prostate Cancer: Highlights from ASCO’s Annual Genitourinary Cancers Symposium and the ODAC Votes Against Extended Use of Xgeva - On Demand
  February 23, 2012
  Based on our Pharmacor Prostate Cancer advisory service, Decision Resources is offering this exclusive analyst call entitled Prostate Cancer: Highlights from ASCO’s Annual Genitourinary Cancers Symposium and the ODAC Votes Against Extended Use of Xgeva.
  
  This analyst call was recorded live on February 23, 2012.  Contact us to learn how you can access the recorded playback.
  
  Click here to view the invite.
  
  
  Read More
• Breast Cancer: The Emergence of Pertuzumab, Highlights from SABCS and Other Recent Market Events - On Demand
  December 20, 2011
  Based on our Pharmacor Breast Cancer advisory service, Decision Resources is offering this exclusive analyst call entitled Breast Cancer: The Emergence of Pertuzumab, Highlights from SABCS and Other Recent Market Events.
  
  This analyst call was recorded live on December 20, 2011.  Contact us to learn how you can access the recorded playback.
  
  Click here to view the invite.
  
  
  Read More
• Interferon-Free Therapies for Hepatitis C Virus Take Center Stage - Highlights from AASLD’s 2011 Liver Meeting - On Demand
  December 1, 2011
  Based on our Pharmacor Hepatitis C Virus advisory service, Decision Resources is offering this exclusive analyst call entitled Interferon-Free Therapies for Hepatitis C Virus Take Center Stage - Highlights from AASLD’s 2011 Liver Meeting.
  
  This analyst was recorded live on December 1, 2011.  Contact us to learn how you can access the recorded playback.
  
  Click here to view the invite.
  
  
  Read More
• Mixed Fortunes for Xarelto and Vorapaxar in Acute Coronary Syndrome – What Does the Future Hold for These Novel Oral Antithrombotics? - On Demand
  November 29, 2011
  Based on our Pharmacor advisory service entitled Acute Coronary Syndrome, Decision Resources is offering this exclusive analyst call entitled Mixed Fortunes for Xarelto and Vorapaxar in Acute Coronary Syndrome – What Does the Future Hold for These Novel Oral Antithrombotics?
  
  This analyst call was recorded live on November 29, 2011.  Contact us to learn how you can access the recorded playback.
  
  Click here to view the invite.
  
  
  Read More
• Prostate Cancer: Navigating Through the Maze of Market-Relevant Patient Populations - On Demand
  October 26, 2011
  Based on our Pharmacor Prostate Cancer advisory service, Decision Resources is offering an exclusive analyst call entitled Prostate Cancer: Navigating Through the Maze of Market-Relevant Patient Populations.
  
  This analyst call was recorded live on October 26, 2011.  Contact us to learn how you can purchase this service and access the recorded playback.
  
  Click here to view the invite.
  
  
  Read More
• Ovarian Cancer: Avastin Will Revolutionize Therapeutic Options and Will Pave the Way for Targeted Therapy Approvals - On Demand
  October 25, 2011
  Based on our Pharmacor Ovarian Cancer advisory service, Decision Resources is offering this exclusive analyst call entitled Ovarian Cancer: Avastin Will Revolutionize Therapeutic Options and Will Pave the Way for Targeted Therapy Approvals.
  
  This analyst call was recorded live on October 25, 2011.  Contact us to learn how you can access the recorded playback.
  
  Click here to view the invite.
  
  
  Read More
• Targeted Therapies in Breast Cancer – Everolimus Takes Center Stage at ECCO-ESMO - On Demand
  October 18, 2011
  Based on our Pharmacor Breast Cancer advisory service, Decision Resources is offering this exclusive analyst call entitled Targeted Therapies in Breast Cancer – Everolimus Takes Center Stage at ECCO-ESMO.
  
  This analyst call was recorded live on October 18, 2011.  Contact us to learn how you can purchase this service and access the recorded event.
  
  Click here to view the invite.
  
  
  Read More
• Atrial Fibrillation: Will Emerging Agents With Novel Mechanisms of Action Overcome the Limitations of Current Treatments? - On Demand
  August 16, 2011
  Based on our Pharmacor Atrial Fibrillation advisory service, Decision Resources is offering an exclusive analyst call entitled Atrial Fibrillation: Will Emerging Agents With Novel Mechanisms of Action Overcome the Limitations of Current Treatments?
  
  This analyst call was held on August 16, 2011. Contact us to learn how you can purchase this service and access the recorded event.
  
  Click here to view the invite.
  
  
  Read More
• Merck Serono Abandons Oral Cladribine: What Impact Will Its Termination Have on the Multiple Sclerosis Drug Market? - On Demand
  July 6, 2011
  Based on our Pharmacor Multiple Sclerosis advisory service, Decision Resources is offering an exclusive analyst call entitled Merck Serono Abandons Oral Cladribine: What Impact Will Its Termination Have on the Multiple Sclerosis Drug Market?
  
  This analyst call was held on July 6, 2011. Contact us to learn how you can purchase this service and access the recorded event.
  
  Click here to view the invite.
  
  
  Read More
Displaying results 1-10 (of 96)
 |<  < 1 2 3 4 5 6 7 8 9 10  >  >|